Upadacitinib: Mechanism of action, clinical, and translational science

• Main Authors: Mohamed‐Eslam F. Mohamed (Author), Sumit Bhatnagar (Author), Julie M. Parmentier (Author), Priscila Nakasato (Author), Peter Wung (Author)
• Format: Book
• Published: Wiley, 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Upadacitinib is a selective Janus kinase (JAK) inhibitor which is approved by the US Food and Drug Administration, the European Medicines Agency, as well as other agencies around the world for the treatment of several chronic inflammatory diseases, including rheumatic, dermatologic, and gas...